난소암 : KOL 인사이트

KOLs critically assess the evolving landscape of ovarian cancer treatment, including the sustained importance of PARP inhibitors like Lynparza, emerging competition from antibody-drug conjugates (ADCs), and the future potential of novel therapies such as saruparib and next-generation PARPis. Explore the promising outcomes of ImmunoGen's Elahere in platinum-resistant settings and the cautious optimism surrounding AstraZeneca's Enhertu, among others. However, significant challenges remain, particularly for immunotherapy combinations and certain experimental treatments.

Key brands covered in this report:

Companies:

Novartis, Lilly, Roche, GSK, AstraZeneca, Pfizer, Merck, Merck & Co., Bristol Myers Squibb, Genentech, Daiichi Sankyo, ImmunoGen, Menarini, Johnson & Johnson Innovative Medicine, Merck Group, Corcept Therapeutics, Ono Pharmaceutical, Alkermes, Zymeworks, OncoQuest, Gradalis, Verastem Oncology, Sutro Biopharma, Genelux, pharma&, Antengene, Artios Pharma, Karyopharm Therapeutics, Klus Pharma, Zentalis Pharmaceuticals.

Key questions answered:

• What are the current backbone treatments for ovarian cancer, and what are their pros and cons?
• How does the medical community view PARP inhibitors like Lynparza, Rubraca, and Zejula in terms of efficacy, tolerability, and ease of use, and how might their usage change?
• Which recent or ongoing clinical trials could significantly impact prescribing trends, and what will their results mean for the future of ovarian cancer treatment?
• What must emerging targeted therapies demonstrate to become the preferred treatments for specific patient segments, and are they likely to meet these criteria?
• Which pipeline products show the most promise, and how will they affect current market players?

Table of Contents

Executive summary

Current and future treatment algorithm

Research objectives

Marketed products

• PARPis
  • Insights for the PARPis (Lynparza, Rubraca, Zejula)
  • Lynparza (olaparib; AstraZeneca/Merck & Co.)
  • Rubraca (rucaparib; Pharma& Schweiz)
  • Zejula (niraparib; GSK)
• ADC/tubulin/DNA topoisomerase I inhibitors
  • Insights for the ADC/tubulin/DNA topoisomerase I inhibitors
  • Elahere (mirvetuximab soravtansine; ImmunoGen)
  • Enhertu (trastuzumab deruxtecan; AstraZeneca/Daiichi Sankyo)

Pipeline products

• Immune checkpoint inhibitors (ICI)
  • Insights for the ICI class
  • Bavencio (avelumab; Merck Group)
  • Imfinzi (durvalumab; AstraZeneca)
  • Jemperli (dostarlimab; GSK)
  • Keytruda (pembrolizumab; Merck & Co.)
  • Opdivo/Yervoy (nivolumab/ipilimumab; BMS/Ono)
  • Tecentriq (atezolizumab; Roche)
  • Immunostimulants
  • Insights for the immunostimulants
  • Oregovomab (anti-idiotype mAb; OncoQuest)
• Therapeutic vaccines
  • Insights for the therapeutic vaccines
  • Olvi-Vec (olvimulogene nanivacirepvec; Genelux Corporation)
  • Vigil (Bi-shRNAfurin-GM-CSF-loaded tumour cell vaccine; Gradalis)
• Next-generation ADCs
  • Insights for the next-generation ADCs
  • STRO-002 (luveltamab tazevibulin; Sutro Biopharma)
  • R-DXd (raludotatug deruxtecan; Daiichi Sankyo/Merck & Co.)
• Other late-stage modalities
  • Insights on MAP/RAF/FA kinase inhibitors
  • VS 6766/VS 6063 (avutometinib/defactinib; Verastem Oncology)
• Glucocorticoid receptor antagonists
  • CORT-125134 (relacorilant; Corcept Therapeutics)
• Mid and early-stage modalities
  • Next-generation ADCs and other MOAs
  • ART6043 (Artios Pharma)
  • AZD-5305 (saruparib; AstraZeneca)
  • AZD 6738 (ceralasertib; AstraZeneca)
  • AZD 8205 (AstraZeneca)
  • IMGN 151 (ImmunoGen)
  • KP-2638/ZN-c3 (azenosertib; Zentalis Pharmaceuticals)
  • MK-2870 (sacituzumab tirumotecan; Klus Pharma/Merck & Co)
  • Nexpovio/Xpovio (selinexor; Antengene/Karyopharm Therapeutics/Menarini)
  • Rina-S (rinatabart sesutecan; ProfoundBio)
  • Verzenio/Verzenios (abemaciclib; Eli Lilly and Company)
  • ZW 191 (Zymeworks)

Appendix

• KOL details
  • KOLs from the US
  • KOLs from Europe

News